Zolgensma, Kymriah First Korean Approvals Under New Biologics Law
But Reimbursement Path Still Unclear
Executive Summary
Novartis’s Zolgensma and Kymriah have became the first two drugs to be approved under new South Korean legislation for cutting-edge regenerative medicines and biologics, implemented last year. How the country deals with the reimbursement of these drugs is expected to determine the regulatory path for other ultra high-priced drugs such as gene therapies.
You may also be interested in...
Japan To Reimburse Zolgensma – But At Lower Price Than US
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.
New Korean Law On Cutting-Edge Biologics Raise Hopes And Concerns
A new South Korean law to support and manage the safety of cutting-edge regenerative medicines and biologics has been passed amid hopes these will become a national growth engine, although there are concerns that a further easing of rules could lead to another 'Invossa incident'.
Diversification, Tailored Services Seen Key For CDMOs
Korea's Samsung Biologics talked during the BIO Digital event about the key trends and new paradigms in the CDMO industry in the COVID-19 era, including expansion, diversification and personalization. Forward planning helped overcome pandemic-related challenges but logistics remains a major challenge.